Since 2021, Matt has been included in the prestigious <em>IAM Strategy 300</em>, which recognizes leaders in IP strategy and value creation worldwide.

Matthew S. Bodenstein

Director

mbodenstein@sternekessler.com
+1 202.772.8787
LinkedIn

Overview

Matt Bodenstein is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group where he advises a diverse range of clients in the chemical, pharmaceutical, food science, material science, and biotechnology spaces. He has been recognized by his clients and peers as a leading patent strategist and is well-known for his thoughtful and creative approaches to obtaining business-critical patents.

Matt’s practice includes assisting clients with creating and managing strategic patent portfolios, managing complex and high priority patent prosecution (including “Track 1” applications), conducting and managing complex due diligence investigations in connection with potential investments, acquisitions, and licensing opportunities, and rendering freedom to operate, validity, and non-infringement opinions.

In addition to his focus on pure patent matters, Matt regularly helps clients negotiate term sheets, license agreements, and other strategic transactions.

Prior to joining Sterne Kessler, Matt was Intellectual Property Counsel for the former Medicis Pharmaceutical Corp., and an associate and patent agent in the IP Group of an AmLaw 100 law firm.

Before becoming a lawyer, Matt worked in the CNS Medical Chemistry group at Pfizer, Inc. and the Process Research and Development Group at Merck & Co., Inc.

Matt earned his J.D., cum laude, from Temple University Beasley School of Law, and his M.S. and B.A. degrees in Chemistry, from the University of Pennsylvania.

Outside of work, Matt can often be found walking his Great Pyrenees/hound mix, Ripley, relaxing with his family at a Nats or DC United game, or cranking away on his bike (look for him on Zwift!).

Accolades

  • IAM Strategy 300, “Global Leaders Guide” (2023 – 2021)
  • IAM Strategy 300, “A Guide to the World’s Leading IP Strategists” (2023 – 2021)

Education

  • J.D., Temple University Beasley School of Law, cum laude
  • M.S., Organic Chemistry, University of Pennsylvania
  • B.A., Chemistry, University of Pennsylvania

Admissions

  • District of Columbia
  • Pennsylvania
  • U.S. District Court for the Eastern District of Pennsylvania
  • United States Patent & Trademark Office

Events

Speaking Engagement 2023 Focus on Pharma Washington, DC, April 14, 2023
Speaking Engagement 2019 Global IP Strategy Conference Washington, DC, March 15, 2019

Related Resources From Matthew S. Bodenstein

Press Release Prestigious IAM Strategy 300 Features Five Sterne Kessler Attorneys in 2023 Guide Sterne, Kessler, Goldstein & Fox September 28, 2023
Press Release Directors Bodenstein, Durkin, and Sterne Recognized as 2023 IAM Strategy 300 Global Leaders Sterne, Kessler, Goldstein & Fox December 19, 2022
Press Release Directors Bodenstein, Durkin and Sterne Ranked Among Global IP Leaders in 2022 IAM Strategy 300 Sterne, Kessler, Goldstein & Fox September 12, 2022
Press Release Four Sterne Kessler Directors Featured in IAM Strategy 300 Global Leaders 2022 Guide Sterne, Kessler, Goldstein & Fox January 17, 2022
Press Release Directors Bodenstein, Durkin, Ellison, and Sterne Ranked in 2021 IAM Strategy 300 Sterne, Kessler, Goldstein & Fox August 31, 2021
Press Release Sterne Kessler Attorneys Author U.S. Chemical Patent Law Sterne, Kessler, Goldstein & Fox P.L.L.C October 1, 2019
In the News Law360 Names Attys Who Moved Up The Firm Ranks in Q1 fivejars April 28, 2017
Press Release Sterne, Kessler, Goldstein & Fox Elects Five New Directors fivejars January 16, 2017